Recalcitrant Grover’s Disease Successfully Managed with Dupilumab and Naltrexone in a Middle-Aged Woman: A Case Study

Main Article Content

Kaylin Beiter
Christy Behnam
Bridget Shields

Keywords

Dupilumab, Grover's Disease, Female, Transient Acantholytic Dermatosis

Abstract

Introduction: Grover’s disease, or transient acantholytic dermatosis, is a common benign papulovesicular disorder that often affects elderly men. It is typically managed with topical therapeutics in this population. We present here an uncommon case of Grover’s disease, occurring in a relatively younger patient, that was recalcitrant to typical therapeutics modalities.


Case Report: A 45-year-old woman presented to our clinic with a several month history of discrete, pink, ill-defined pruritic papules on her torso with sparing of her extremities. Grover’s disease was diagnosed based on her clinical presentation and subsequently biopsy-confirmed. She failed multiple topical medications, oral acitretin, and only experience minimal relief when transitioned to Naltrexone. Dupilumab was added to her regimen, with rapid improvement. She was eventually transitioned down to dupilumab monotherapy, and has remained clear since. 


Conclusion: Grover’s disease is not common among middle-aged women. Novel therapies, such as biologics, have been efficacious in elderly (especially male) populations with this condition. Our case demonstrates the importance of attempting new treatment modalities such as dupilumab for patients with recalcitrant disease. Novel application of these biologic treatments may be needed in particular for atypical cases, such as when patients do not fit the known epidemiologic profile.

References

1. Aldana PC, Khachemoune A. Grover disease: review of subtypes with a focus on management options. Int J Dermatol. 2020;59(5):543-550. doi:10.1111/ijd.14700

2. French LE, Piletta PA, Etienne A, Salomon D, Saurat JH. Incidence of transient acantholytic dermatosis (Grover’s disease) in a hospital setting. Dermatology1. 1999;198(4):410-411.

3. Scheinfeld N, Mones J. Seasonal variation of transient acantholytic dyskeratosis (Grover’s disease). J Am Acad Dermatol. 2006;55(2):263-268. doi:10.1016/j.jaad.2006.01.029

4. Bellinato F, Maurelli M, Gisondi P, Girolomoni G. Clinical features and treatments of transient acantholytic dermatosis (Grover’s disease): a systematic review. J Ger Soc Dermatology. 2020;18(8):826-833. doi:10.1111/ddg.14202

5. Butler DC, Kollhoff A, Berger T. Treatment of Grover Disease With Dupilumab. JAMA Dermatology. 2021;157(3):353-356. doi:10.1001/jamadermatol.2020.5097

6. Barei F, Torretta S, Morini N, Ferrucci S. A case of Grover disease treated with Dupilumab: Just serendipity or a future perspective? Dermatol Ther. 2022;35(5):e15429. doi:10.1111/dth.15429

7. Brummer GC, Wang LT, Sontheimer RD. A possible role for dupilumab (Dupixent) in the management of idiopathic chronic eczematous eruption of aging. Dermatol Online J. 2018;24(2):13030/qt55z1f6xh.

8. Shelton E, Doolittle C, Shinohara MM, Thompson JA, Moshiri AS. Can’t handle the itch? Refractory immunotherapy-related transient acantholytic dermatosis: prompt resolution with dupilumab. JAAD Case Reports. 2022;22:31-33. doi:10.1016/j.jdcr.2022.01.029

9. Valiathan R, Ashman M, Asthana D. Effects of Ageing on the Immune System: Infants to Elderly. Scandanavian J Immunol. 2016;83(4):255-266. doi:10.1111/sji.12413

10. Han A, Kim JY, Kwak-Kim J, Lee SK. Menopause is an inflection point of age-related immune changes in women. Joural Reprod Immunol. 2021;146:103346. doi:10.1016/j.jri.2021.103346

11. Lee B, Elston DM. The uses of naltrexone in dermatologic conditions. J Am Acad Dermatol. 2019;80(6):1746-1752. doi:10.1016/j.jaad.2018.12.031

12. Lee J, Shin JU, Noh S, Park CO, Lee KH. Clinical Efficacy and Safety of Naltrexone Combination Therapy in Older Patients with Severe Pruritus. Ann Dermatol. 2016;28(2):159-163. doi:10.5021/ad.2016.28.2.159